Merck: Phase III trial in lung cancer fails
(CercleFinance.com) - Merck announces that, on the recommendation of an independent data monitoring committee, it has stopped the KeyVibe-008 phase III trial for the first-line treatment of patients with extensive-stage small-cell lung cancer.
This trial evaluated the investigational fixed-dose combination of vibostolimab and pembrolizumab (Keytruda), in combination with chemotherapy, versus atezolizumab in combination with chemotherapy.
Data showed that the primary endpoint of overall survival met pre-specified futility criteria, as well as higher rates of adverse events, including immune-related events, than in the control arm.
Merck therefore warns that patients in the study should discontinue fixed-dose vibostolimab and pembrolizumab and be offered the option of atezolizumab. Results will be shared with the scientific community.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This trial evaluated the investigational fixed-dose combination of vibostolimab and pembrolizumab (Keytruda), in combination with chemotherapy, versus atezolizumab in combination with chemotherapy.
Data showed that the primary endpoint of overall survival met pre-specified futility criteria, as well as higher rates of adverse events, including immune-related events, than in the control arm.
Merck therefore warns that patients in the study should discontinue fixed-dose vibostolimab and pembrolizumab and be offered the option of atezolizumab. Results will be shared with the scientific community.
Copyright (c) 2024 CercleFinance.com. All rights reserved.